Patients with metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-sensitizing mutations generally receive EGFR-tyrosine kinase inhibitors (TKIs) as the first-line treatment [1]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.